Amgen, Inc. vs Digital Realty Trust, Inc. — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while Digital Realty Trust, Inc. trades at $180 (market cap $66.75B). The key difference: Amgen, Inc. is far larger — about 2.9× Digital Realty Trust, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | DLR | |
|---|---|---|
Market Cap | $196.12B | $66.75B |
Sector | Health | Real Estate |
52-Week High | $388.16 | $203.91 |
52-Week Low | $271.18 | $147.93 |
Enterprise Value | $241.41B | $84.27B |
Dividend Yield | 2.77% | 2.7% |
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Digital Realty Trust (DLR) trades at $180.41, up 0.6% on the day, with a bearish technical signal despite strong analyst consensus. The stock shows robust fundamentals with revenue growth to $6.11B in 2025 and net income margin of 21.73%, though valuation ratios like P/E of 47.85 appear elevated. Recent news highlights a $7.8B acquisition of Blackstone's data center stake, expanding its hyperscale portfolio amid AI-driven demand.
Outlook remains positive with a consensus price target of $218.77, implying 21% upside, supported by AI infrastructure expansion. Key risks include high debt levels, execution challenges from recent deals, and interest rate sensitivity. Institutional sentiment is bullish with 60% buy ratings, but technical weakness near support at $178 warrants caution.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →